A Phase I, Single Dose, Open-Label, Sequential Group Study Comparing the Pharmacokinetics and Safety of PA-824 in Subjects With Mild, Moderate, and Severe Hepatic Impairment to Matched, Non-Hepatically Impaired Subjects

Trial Profile

A Phase I, Single Dose, Open-Label, Sequential Group Study Comparing the Pharmacokinetics and Safety of PA-824 in Subjects With Mild, Moderate, and Severe Hepatic Impairment to Matched, Non-Hepatically Impaired Subjects

Suspended
Phase of Trial: Phase I

Latest Information Update: 14 Oct 2015

At a glance

  • Drugs Pretomanid (Primary)
  • Indications Tuberculosis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 09 Oct 2015 Status changed from recruiting to suspended as reported by ClinicalTrials.gov
    • 02 Oct 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
    • 04 Sep 2015 Study design has been changed from parallel group to sequential study group.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top